Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms

Autor: Van 'T Veer, Laura, Drukker, CA, Nijenhuis, MV, Bueno-de-Mesquita, JM, Retel, VP, van, WH, van, H, Wesseling, J, Schmidt, MK, van't, LJ, Sonke, GS

Publikováno v: Van 'T Veer, Laura; Drukker, CA; Nijenhuis, MV; Bueno-de-Mesquita, JM; Retel, VP; van, WH; et al.(2014). Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/4st3j4pq

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::33b8295d461ff21411922428737ec21c
http://www.escholarship.org/uc/item/4st3j4pq

Mammographic screening detects low-risk tumor biology breast cancers

Autor: Esserman, Laura, Van 'T Veer, Laura, Kerlikowske, Karla, Drukker, CA, Schmidt, MK, Rutgers, EJT, Cardoso, F, Esserman, LJ, Van, FE, Pijnappel, RM, Slaets, L, Bogaerts, J

Publikováno v: Esserman, Laura; Van 'T Veer, Laura; Kerlikowske, Karla; Drukker, CA; Schmidt, MK; Rutgers, EJT; et al.(2014). Mammographic screening detects low-risk tumor biology breast cancers. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/28b4s2cv

Overdiagnosis of breast cancer, i.e. the detection of slow-growing tumors that would never have caused symptoms or death, became more prevalent with the implementation of population-based screening. Only rough estimates have been made of the proporti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::65a9c6da8e4356282b3b9bf737f43c7c
http://www.escholarship.org/uc/item/28b4s2cv

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

Autor: Nederlof I; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Isaeva OI; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Graaf M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Gielen RCAM; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Bakker NAM; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Rolfes AL; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Garner H; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Boeckx B; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.; VIB Center for Cancer Biology, Leuven, Belgium., Traets JJH; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Mandjes IAM; Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Maaker M; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Brussel T; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.; VIB Center for Cancer Biology, Leuven, Belgium., Chelushkin M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Champanhet E; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lopez-Yurda M; Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van de Vijver K; Department of Pathology, UZ Gent - Universitair Ziekenhuis Gent, Gent, Belgium.; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van den Berg JG; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hofland I; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Klioueva N; Department of Pathology, OLVG Hospital, Amsterdam, the Netherlands., Mann RM; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Loo CE; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Duijnhoven FH; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Skinner V; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Luykx S; Medical Oncology Department, Tergooi Hospital - locatie Hilversum, Hilversum, the Netherlands., Kerver E; Department of Oncology, OLVG Hospital, Amsterdam, the Netherlands., Kalashnikova E; Natera, San Carlos, CA, USA., van Dongen MGJ; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Linn SC; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Blank CU; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Visser KE; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands., Salgado R; Department of Pathology, ZAS hospitals, Antwerp, Belgium.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Wessels LFA; Oncode Institute, Utrecht, the Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Drukker CA; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Schumacher TN; Oncode Institute, Utrecht, the Netherlands.; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands., Horlings HM; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lambrechts D; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.; VIB Center for Cancer Biology, Leuven, Belgium., Kok M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.

Publikováno v: Nature medicine [Nat Med] 2024 Nov; Vol. 30 (11), pp. 3223-3235. Date of Electronic Publication: 2024 Sep 16.

Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.

Autor: van Olmen JP; Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Jacobs CF; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Bartels SAL; Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Loo CE; Department of Radiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Sanders J; Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Vrancken Peeters MTFD; Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Drukker CA; Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., van Duijnhoven FH; Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Kok M; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands. Electronic address: m.kok@nki.nl.

Publikováno v: Breast (Edinburgh, Scotland) [Breast] 2024 Jun; Vol. 75, pp. 103726. Date of Electronic Publication: 2024 Apr 05.

Management of Benign Phyllodes Tumors: A Dutch Population-Based Retrospective Cohort Between 1989 and 2022.

Autor: van Olmen JP; Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Beerthuizen AWJ; Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Bekers EM; Department of Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Viegen I; Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Drukker CA; Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Vrancken Peeters MTFD; Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Bartels SAL; Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands., van Duijnhoven FH; Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands. f.v.duijnhoven@nki.nl.

Publikováno v: Annals of surgical oncology [Ann Surg Oncol] 2023 Dec; Vol. 30 (13), pp. 8344-8352. Date of Electronic Publication: 2023 Aug 28.